Skip to main content

Article: "Israeli migraine device proves ‘effective, safe, sustainable’ in real-world study”

January 25, 2022


The Nerivio remote electrical neuromodulation (REN) device, made by Israeli American digital therapeutics company Theranica, proved safe and effective at treating migraine symptoms in the world’s largest prospective real-world study of such treatment. The study consisted of over 23,000 treatments in thousands of patients over 20 months, with 80% of treatments excluding prescription migraine medication. Results of the study showed over 65% of participants experienced pain relief after two hours, 66% of treatments required no additional medication, and no need to increase electrical intensity of the device over time.

The device, placed on the upper arm at the beginning of a migraine attack, stimulates peripheral nerves with small electrical currents and triggers conditioned pain modulation. The device can be controlled through a smartphone app and currently has over 25,000 American users. Nerivio was approved by the FDA in May 2019 for individuals over 12 years of age. It offers migraine treatment concurrently with other medications, or as a standalone treatment for those that cannot take prescription or over-the-counter migraine medication because of side effects or other drug-drug interactions.

To read the full article, click here:

*Image used is from the original news article published by The Jerusalem Post. Nerivio device (photo credit: THERANICA)